Financial incentives linked to self-assessment of prescribing patterns: A new approach for quality improvement of drug prescribing in primary care

Quality in Primary Care

Volumn 17, Issue 3, 2009, Pages 179-189

  Wettermark, Björn ^a,b,c   Pehrsson, Åke ^c   Juhasz Haverinen, Maria ^c   Veg, Aniko ^d   Edlert, Maria ^c   Törnwall Bergendahl, Gunilla ^c   Almkvist, Henrik ^c   Godman, Brian ^e   Granath, Fredrik ^b   Bergman, Ulf ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

General practice; Incentives; Prescribing; Primary health care; Quality indicators

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ATENOLOL; BENDROFLUMETHIAZIDE; BUDESONIDE; CITALOPRAM; CYANOCOBALAMIN; ENALAPRIL; FELODIPINE; FUROSEMIDE; LEVOTHYROXINE SODIUM; METFORMIN; METOPROLOL; OMEPRAZOLE; PARACETAMOL; PROPIOMAZINE; RAMIPRIL; SIMVASTATIN; TERBUTALINE; ZOPICLONE;

ARTICLE; CLINICAL INDICATOR; COST CONTROL; DRUG SAFETY; DRUG UTILIZATION; FINANCIAL MANAGEMENT; HEALTH CARE QUALITY; MEDICAL DOCUMENTATION; METHODOLOGY; PHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; SWEDEN;

DRUG PRESCRIPTIONS; GUIDELINE ADHERENCE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; REIMBURSEMENT, INCENTIVE;

EID: 67651163814     PISSN: 14791072     EISSN: 14791064     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Thorpe KE. The rise in health care spending and what to do about it. Health Affairs 2005;24:1436-1445
2. Zuvekas SH and Cohen JW. Prescription drugs and the changing concentration of health care expenditures. Health Affairs 2007;26:249-257
3. Ess SM, Schneeweiss S and Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21:89-103. (Pubitemid 36127005)
4. Garattini L, Motterlini N and Cornago D. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. Health Policy 2008;85:305-313 (Pubitemid 351179534)
5. Henriksson F, Hjortsberg C and Rehnberg C. Pharmaceutical expenditure in Sweden. Health Policy 1999:47;125-144
6. Godman B, Wettermark B, Hoffmann et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Review of Pharmacoeconomics and Outcomes Research 2009;9:65-83.
7. Lee T and Emanuel E. Tier 4 drugs and the fraying of the social compact. New England Journal of Medicine 2008;359:333-335
8. Freemantle N and Bloor K. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients. BMJ 1996;312:1469-1471
9. Bloor K and Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctors. BMJ 1996;312:1525-1527
10. Bloor K, Maynard A and Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry. BMJ 1996;313:33-35
11. Grimshaw JM, Thomas RE, MacLennan G et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment 2004;8(6):iii-iv, 1-72. (Pubitemid 38279464)
12. Fattore G and Jommi C. The last decade of Italian pharmaceutical policy: instability or consolidation? Pharmacoeconomics 2008;26:5-15.
13. Chapman S, Durieux P and Walley T. Good prescribing practice. In: Elias Mossialos, Monique Mrazek and Tom Walley (eds) Good Prescribing Practice in Regulating Pharmaceuticals in Europe: striving for efficiency, equity and quality. Buckingham: Open University Press, 2004, pp. 144-157
14. Hyde R. Doctors to pay for patients' medicines in Germany. The Lancet 2007;370:1118.
15. Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Review of Pharmacoeconomics and Outcomes Research 2008;8:357-371
16. Walley T, Mrazwek M and Mossialos E. Regulating pharmaceutical markets: Improving efficiency and controlling costs in the UK. International Journal of Health Planning and Management 2005;20:375-398 (Pubitemid 41762891)
17. Harris C and Scrivener G. Fundholders' prescribing costs: the first five years. BMJ 1996;313:1531-1534 (Pubitemid 27016892)
18. Walley T and Mossialos E. Financial incentives and prescribing. In: Elias Mossialos, Monique Mrazek and Tom Walley (eds) Financial Incentives and Prescribing in Regulating Pharmaceuticals in Europe: striving for efficiency, equity and quality. Buckingham: Open University Press, 2004, pp. 177-195
19. Mason A, Towse A, Drummond M and Cooke J. Influencing Prescribing in a Primary Care Led NHS. London: Office of Health Economics, 2002.
20. Wallack S, Weinberg DB and Thomas CP. Health plans' strategies to control prescription drug spending. Health Affairs 2004;23:141-148 (Pubitemid 39531461)
21. Martens J, Werkhiven M, Severens J and Winkens R. Effects of a behaviour independent financial incentive on prescribing behaviour of general practitioners. Journal of Evaluation in Clinical Practice 2007;13:369-373 (Pubitemid 46789637)
22. Sjöqvist F, Bergman U, Dahl M-L et al. Drug and therapeutics committees: a Swedish experience. WHO Drug Information 2002;16:207-213 (Pubitemid 36262226)
23. Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008;26:537-550 (Pubitemid 351871549)
24. Bergström G and Karlberg I. Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. Health Policy 2007;81:358-367
25. Wettermark B, Bergman U and Krakau I. Using aggregate data on dispensed drugs to evaluate the quality of prescribing in urban primary healthcare in Sweden. Public Health 2006;120:451-461
26. Bergman U, Andersson D, Friberg A et al. Quality indicators for drug use and drug handling. Issued by the Medical Quality Council founded by the Swedish Society of Medicine and the Swedish Medical Association. Svensk Median 1999;66.
27. WHO Collaborationg Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2007
28. Wettermark B, Pehrsson Å, Jinnerot D and Bergman U. Drug utilisation 90% profiles - a useful tool for quality assessment of prescribing in primary healthcare in Stockholm. Pharmacoepidemiology and Drug Safety 2003;12:499-510.
29. Wettermark B, Nyman K and Bergman U. Five years' experience of quality assurance and feedback with individual prescribing profiles at a primary healthcare centre in Stockholm, Sweden. Quality in Primary Care 2004;12:225-234
30. Wettermark B. Drug Utilization 90% - Using Aggregate Drug Statistics for the Quality Assessment of Prescribing. PhD thesis. Stockholm: Karolinska Institutet, Stockholm 2004.
31. Anon. Wise Drug List (Kloka Listan): physician version [in Swedish]. Stockholm: Stockholm County Council, Regional Drug and Therapeutics Committee, 2007. www.janusinfo.se/klokalistan/external/baselist.asp (accessed 20 April 2009).
32. Grimshaw J, Campbell M, Eccles M and Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Family Practice 2000;17:S11-S18. (Pubitemid 30105646)
33. Stephenson J and Imrie J. Why do we need randomised controlled trials to assess behavioural interventions? BMJ 1998;316:611-613
34. Beishon J, McBride T, Scharaschkin S et al. The National Audit Office. Prescribing Costs in Primary Care. London: The Stationery Office, 2007. www.nao.org.uk/publications/0607/prescribing-costs-in-primary-c.aspx (accessed 20 April 2009).
35. Bero LA, Grilli R, Grimshaw JM et al. The Cochrane Effective Practice and Organization of Care Review Group. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1998;317:465-468
36. O'Connell DL, Henry D and Tomlins R. Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. BMJ 1999;318:507-11. (Pubitemid 29188995)
37. Söndergaard J, Andersen M, Stövring H and Kragstrup J. Mailed prescriber feedback in addition to a clinical guideline has no impact: a randomised, controlled trial. Scandinavian Journal of Primary Healthcare 2003;21:47-51. (Pubitemid 36389481)
38. Mason J, Freemantle N, Nazareth I et al. When is it cost-effective to change the behaviour of health professionals. Journal of the American Medical Association 2001;286:2988-2992 (Pubitemid 33140363)
39. Wettermark B, Godman B, Jacobsson B and Haaijer-Ruskamp F. Soft regulations in pharmaceutical policy making - an overview of current approaches and their consequences. Applied Health Policy and Health Economy 2009;in press.
40. Usher-Smith JA, Ramsbottom T, Pearmain H and Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. International Journal of Clinical Practice 2007;61:15-23. (Pubitemid 46269345)
41. Usher-Smith J, Ramsbottom T, Pearmain H and Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. International Journal of Clinical Practice 2008;62:480-484 (Pubitemid 351197428)
42. Wessling A and Lundin D. The review of drugs against disease caused by acid stomach - a summary. Solna: Pharmaceuticals Benefits Board, 2006. www.tlv.se/upload/genomgangen/summary-stommach-acid.pdf
43. Office of Fair Trading (UK). The Pharmaceutical Price Regulation System: an OFT study. Annexe A: Market for prescription pharmaceuticals in the NHS. London: The Office of Fair Trading, 2007. www.oft.gov.uk/shared-oft/reports/ comp-policy/oft885a.pdf (accessed 20 April 2009).
44. Sturm H, Austvoll-Dahlgren A, Aaserud M et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database of Systematic Reviews 2007;(3):CD006731. (Pubitemid 351805597)
45. Mason AR, Drummond MF, Hunter JA, Towse AK and Cooke J. Prescribing incentive schemes: a useful approach? Applied Health Economics and Health Policy 2005;4:111-17.
46. Chaix-Couturier C, Durand-Zaleski I, Jolly D and Durieux P. Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues. International Journal of Quality in Health Care 2000;12:133-142 (Pubitemid 30262229)
47. Adams AS, Soumerai SB, Lomas J and Ross-Degnan D. Evidence of self-report bias in assessing adherence to guidelines. International Journal of Quality in Health Care 1999;11:187-192 (Pubitemid 29302446)
48. Kesselheim AS and Brennan TA. Overbilling vs. down-coding - the battle between physicians and insurers. New England Journal of Medicine 2005;352:855-857
49. Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. New England Journal of Medicine 2006;355:375-384 (Pubitemid 44127540)
50. Smith PC and York N. Quality incentives: the case of UK general practitioners. Health Affairs 2004;23:112-118
51. Donabedian A. The quality of care. How can it be assessed? Journal of the American Medical Association 1988;260:1743-1748